Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMG9MN2)

Drug Name

SAR97276 Drug Info

Synonyms

Albitiazolium bromide; UNII-3AC0AJ4ILP; 3AC0AJ4ILP; 321915-72-4; SAR 97276; Albitiazolium bromide [INN]; SCHEMBL2017697; CHEMBL520613; DTXSID60185968; 3,3'-(Dodecan-1,12-diyl)bis(5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium) dibromide; AN-28886; 2-[3-[12-[5-(2-hydroxyethyl)-4-methyl-thiazol-3-ium-3-yl]dodecyl]-4-methyl-thiazol-3-ium-5-yl]ethanol dibromide

Indication

Disease Entry	ICD 11	Status	REF
Malaria	1F40-1F45	Phase 2	[1]

Cross-matching ID

PubChem CID: 11377023
CAS Number: CAS 753439-46-2
TTD Drug ID: DMG9MN2

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Plasmodial phospholipid metabolism (PPP metab)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CDRI-97/78	DM049IX	Malaria	1F40-1F45	Phase 1	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Plasmodial phospholipid metabolism (PPP metab)	TTQ2GJ0	NOUNIPROTAC	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00739206) Study of SAR97276A in the Treatment of Uncomplicated and Severe Malaria in Adults and Children.. U.S. National Institutes of Health.
2	Transport and pharmacodynamics of albitiazolium, an antimalarial drug candidate. Br J Pharmacol. 2012 August; 166(8): 2263-2276.
3	Single Ascending Dose Safety and Pharmacokinetics of CDRI-97/78: First-in-Human Study of a Novel Antimalarial Drug. Malar Res Treat. 2014;2014:372521.